Irina Ostrovnaya

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Comparison of properties of tests for assessing tumor clonality
    Irina Ostrovnaya
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biometrics 64:1018-22. 2008
  2. pmc Clonality: an R package for testing clonal relatedness of two tumors from the same patient based on their genomic profiles
    Irina Ostrovnaya
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Bioinformatics 27:1698-9. 2011
  3. pmc A classification model for distinguishing copy number variants from cancer-related alterations
    Irina Ostrovnaya
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BMC Bioinformatics 11:297. 2010
  4. pmc Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations
    Christoph A Karlo
    From the Genitourinary Imaging Group, Department of Radiology C A K, P L D P, J C, H H, O A, Urology Service, Department of Surgery A A H, P R, Human Oncology and Pathogenesis Program A A H, J J H, Department of Epidemiology and Biostatistics I O, and Department of Medicine, Genitourinary Oncology Service R M, J J H, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Radiology Academic Offices, Room C278, New York, NY 10065
    Radiology 270:464-71. 2014
  5. pmc Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer
    Gopa Iyer
    Memorial Sloan Kettering Cancer Center, Cornell University, New York, NY, USA
    J Clin Oncol 31:3133-40. 2013
  6. pmc Phase II study of everolimus in metastatic urothelial cancer
    Matthew I Milowsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 112:462-70. 2013
  7. pmc A metastasis or a second independent cancer? Evaluating the clonal origin of tumors using array copy number data
    Irina Ostrovnaya
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Stat Med 29:1608-21. 2010
  8. pmc Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy
    Andrea B Apolo
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Natl Cancer Inst 105:499-503. 2013
  9. pmc Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein
    Rachel Kobos
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, USA
    J Pathol 229:743-54. 2013
  10. pmc Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer
    Arjun V Balar
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 31:724-30. 2013

Collaborators

Detail Information

Publications17

  1. pmc Comparison of properties of tests for assessing tumor clonality
    Irina Ostrovnaya
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biometrics 64:1018-22. 2008
    ..Much of the efficiency deficit can be recovered, however, by restricting the allelic imbalance parameter estimate to a prespecified range, assuming that this parameter is in the prespecified range...
  2. pmc Clonality: an R package for testing clonal relatedness of two tumors from the same patient based on their genomic profiles
    Irina Ostrovnaya
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Bioinformatics 27:1698-9. 2011
    ..For LOH profiles, the package contains significance tests. The analysis of copy number profiles includes a likelihood ratio statistic and reference distribution, as well as an option to produce various plots that summarize the results...
  3. pmc A classification model for distinguishing copy number variants from cancer-related alterations
    Irina Ostrovnaya
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BMC Bioinformatics 11:297. 2010
    ..In order to identify important cancer genes CNAs and CNVs must be distinguished. Although the Database of Genomic Variants (DGV) contains a list of all known CNVs, there is no standard methodology to use the database effectively...
  4. pmc Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations
    Christoph A Karlo
    From the Genitourinary Imaging Group, Department of Radiology C A K, P L D P, J C, H H, O A, Urology Service, Department of Surgery A A H, P R, Human Oncology and Pathogenesis Program A A H, J J H, Department of Epidemiology and Biostatistics I O, and Department of Medicine, Genitourinary Oncology Service R M, J J H, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Radiology Academic Offices, Room C278, New York, NY 10065
    Radiology 270:464-71. 2014
    ..To investigate associations between computed tomographic (CT) features of clear cell renal cell carcinoma (RCC) and mutations in VHL, PBRM1, SETD2, KDM5C, or BAP1 genes...
  5. pmc Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer
    Gopa Iyer
    Memorial Sloan Kettering Cancer Center, Cornell University, New York, NY, USA
    J Clin Oncol 31:3133-40. 2013
    ..We sought to define the prevalence and co-occurrence of actionable genomic alterations in patients with high-grade bladder cancer to serve as a platform for therapeutic drug discovery...
  6. pmc Phase II study of everolimus in metastatic urothelial cancer
    Matthew I Milowsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 112:462-70. 2013
    ..To maximize benefit from targeted agents such as everolimus, the preselection of patients based on molecular phenotype is required...
  7. pmc A metastasis or a second independent cancer? Evaluating the clonal origin of tumors using array copy number data
    Irina Ostrovnaya
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Stat Med 29:1608-21. 2010
    ..Our data analyses show that in many cases a strong clonal signal emerges. Sensitivity analyses show that most of the diagnoses are robust when the data are of high quality...
  8. pmc Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy
    Andrea B Apolo
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Natl Cancer Inst 105:499-503. 2013
    ..69) and 0.58 (95% CI = 0.52 to 0.65), respectively, with superiority of the four-variable model compared with the MSKCC risk-score model for OS (the U statistic and its standard deviation were used to calculate the two-sided P = .02)...
  9. pmc Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein
    Rachel Kobos
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, USA
    J Pathol 229:743-54. 2013
    ..More generally, this work establishes a combined integrated genomics/functional genomics strategy to dissect the biology of oncogenic, chimeric transcription factors...
  10. pmc Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer
    Arjun V Balar
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 31:724-30. 2013
    ..This trial evaluated the efficacy and safety of bevacizumab with GCa in advanced UC...
  11. pmc Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network
    A Ari Hakimi
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 19:3259-67. 2013
    ..To investigate the impact of newly identified chromosome 3p21 epigenetic tumor suppressors PBRM1, SETD2, and BAP1 on cancer-specific survival (CSS) of 609 patients with clear cell renal cell carcinoma (ccRCC) from 2 distinct cohorts...
  12. pmc Testing clonal relatedness of tumors using array comparative genomic hybridization: a statistical challenge
    Irina Ostrovnaya
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 16:1358-67. 2010
    ....
  13. doi request reprint Estimating the dose-toxicity curve in completed phase I studies
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Stat Med 30:2117-29. 2011
    ..Confidence intervals around the toxicity probabilities at each dose level are estimated using the cumulative toxicity data. A programming code is included...
  14. doi request reprint Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases
    David Cobrinik
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065
    Genes Chromosomes Cancer 52:1150-66. 2013
    ..Among the acquired lesions, increased TERT copy number and expression appears likely to function in lieu of MYCNA to promote CNS metastasis...
  15. pmc Genome sequencing identifies a basis for everolimus sensitivity
    Gopa Iyer
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 338:221. 2012
    ....
  16. pmc Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers
    Nicolas Girard
    Pao Lab, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 15:5184-90. 2009
    ..Decisions are currently made using the Martini and Melamed criteria, which are mostly based on tumor location and histologic type. New genomic tools could improve the ability to assess tumor clonality...
  17. pmc Evaluation of the clonal origin of multiple primary melanomas using molecular profiling
    Irene Orlow
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Invest Dermatol 129:1972-82. 2009
    ....